HOVON 155
A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of midostaurin to 10-day decitabine in unfit (i.e. HCT-CI ≥ 3) adult AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) patients.
A study in the frame of the masterprotocol of parallel randomized phase II studies in UNFIT- AML/high-risk MDS patients.
Further Studies: Leukemia
Recruitment completed
CLL 17
A prospective, randomized, unblinded, multicenter, phase III study comparing the efficacy and safety of ibrutinib monotherapy versus time-limited therapy with venetoclax plus obinutuzumab or ibrutinib plus venetoclax in patients with previously untreated chronic lymphocytic leukemia (CLL) - CLL17
Recruitment completed
HOVON 150
A multicenter, double-blind, randomized, placebo-controlled phase 3 study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with blast excess-2, with an IDH1 or IDH2 mutation, respectively, who are eligible for intensive chemotherapy.
Recruitment completed
HOVON 156
A phase 3, multicenter, open-label, randomized, study of Gilteritinib versus Midostaurin in combination with induction and consolidation therapy followed by one-year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy.
HOVON 173
Ivosidenib and azacitidine with or without venetoclax in adult patients with newly diagnosed IDH1-mMutated AML or MDS/AML considered ineligible for intensive chemotherapy
HOVON 177
A study to investigate the effect of adding revumenib to treatment with venetoclax + azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not been previously treated and are not eligible for intensive chemotherapy
